Mindset Pharma Added to North American Psychedelics Index
(firmenpresse) - Toronto, Ontario, February 19, 2021 - Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (Mindset or the Company), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-based index provider, Solactive (the "Index").
The Index is designed to provide a measure of the performance of North American publicly listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. The Index is passive, weighing constituent companies according to their market cap, with a number of conditions that prevent the Index becoming dominated by big pharma, and by psychedelics companies with the largest market cap. Additionally, certain index funds, including the Horizons Psychedelic Stock Index ETF, utilize the Index as a benchmark.
James Lanthier, CEO of Mindset commented, Investor interest in the potential therapeutic benefit of psychedelic drugs is increasing rapidly and we are pleased to have been added to Solactives North American Psychedelics Index. This is significant recognition for Mindset as it reflects our position as a progressive and highly innovative company in the psychedelic space. We believe our addition into the Index will lead to increased exposure and improved liquidity for the Company as we continue to develop our novel next-generation psychedelic drug candidates as well as our patent-pending scalable, cost effective psilocybin synthesis process.
Additionally, the Company will be hosting an investor conference call and webcast on Monday February 22, 2021 at 2:00 p.m. EST with James Lanthier, Chief Executive Officer and Joseph Araujo, Chief Science Officer to discuss updates on the Companys scientific programs.
Investors can access the live conference call and webcast by clicking on the event link http://services.choruscall.ca/links/mindsetpharma20210222.html or can dial in using the numbers below.
PARTICIPANT TELEPHONE NUMBERS
Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Germany TF: 0800-180-1954
Callers should dial in 5 - 10 minutes prior to the scheduled start time and simply ask to join your call.
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
Chief Executive Officer
jlanthier(at)mindsetpharma.com
Jason Atkinson
VP, Corporate Development
jatkinson(at)mindsetpharma.com
About Mindset Pharma Inc.
Mindset is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company''s Management''s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management''s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Fokus Mining Intersected 120.30 Meters at 1.12 G/t Au Included in a Broader Segment that Returned 367.45 Meters at 0.72 G/t Au on Hendrick Zone, Galloway">
" alt="Manganese X Energy Discusses An Electrifying Future For Manganese with The Stock Day Podcast">
Datum: 19.02.2021 - 07:15 Uhr
Sprache: Deutsch
News-ID 1564884
Anzahl Zeichen: 4394
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 568 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mindset Pharma Added to North American Psychedelics Index
"
steht unter der journalistisch-redaktionellen Verantwortung von
Mindset Pharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
